An antidiabetic class switch was performed in 9 (9%) patients, for example, from repaglinide to DPP-4 inhibitor or sulfonylurea plus DPP-4 inhibitor to metformin in case of hypoglycemia, and from GLP1 receptor agonist to long-acting insulin plus glinide in case of hyperglycemia. This evidence concerns the gene DPP4 and Hypoglycemia.